Evidence map›Paper›PMID 42125446›Full record

ArticleJournal of the anus, rectum and colon2026

Efficacy of Ninjin'yoeito in Adjuvant Chemotherapy for Colorectal Cancer: A Retrospective Clinical Study with Propensity Score Matching Analysis.

Kenta Kasahara, Junichi Mazaki, Hiroki Sujino, Yu Kuboyama, Ryutaro Udo, Tomoya Tago, Hiroaki Osakabe, Hiroshi Kuwabara, Kenichi Iwasaki, Hiroyuki Koga and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the anus, rectum and colon, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kenta KasaharaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Junichi MazakiDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Hiroki SujinoDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Yu KuboyamaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Ryutaro UdoDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Tomoya TagoDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Hiroaki OsakabeDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Hiroshi KuwabaraDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Kenichi IwasakiDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Hiroyuki KogaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Akishige KanazawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Yuichi NagakawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Adjuvant chemotherapy (AC) is the standard treatment for stage III colorectal cancer (CRC). However, its effectiveness is limited owing to adverse effects, particularly chemotherapy-induced peripheral neuropathy (CIPN). The objective of this study was to evaluate the real-world efficacy of Ninjin'yoeito (NYT), a traditional Kampo medicine, in improving chemotherapy tolerance and reducing adverse effects during AC with capecitabine plus oxaliplatin (CAPOX). Methods: Fifty-eight patients undergoing AC with CAPOX for CRC were retrospectively analyzed. The patients were divided into two groups: those who received NYT (N group) and those who did not receive NYT (C group). Propensity score matching (PSM) was performed to minimize baseline differences. Outcomes, including appetite loss, fatigue, CIPN, and relative dose intensity (RDI), were compared between the groups. Results: According to the post-matching analysis, the N group demonstrated significant reductions in appetite loss (Grade ≥1:16 vs. 10; Conclusion: NYT could improve AC outcomes by reducing adverse effects and supporting a higher RDI, particularly in patients with frailty.

Indexed as

adjuvant chemotherapycolorectal cancerNinjin'yoeitorelative dose intensity

Identifiers

PMID42125446
PMCPMC13160566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.